286 results about "Asthma" patented technology

Described herein are novel and improved antibodies that bind to thymic stromal lymphopoietin (TSLP) and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP. In certain aspects, described herein are methods of treating asthma by administering anti-TSLP antibodies.

The invention relates to the field of biological medicine, and discloses a method and system for analyzing cough sound by using disease characteristics to diagnose respiratory diseases, and the method comprises the steps: deploying a six-microphone annular array to achieve the precise positioning and triggering of a sound source; self-adaptive spectral subtraction and Wiener filtering cascade are adopted to enhance the audio; segmenting a cough segment based on energy envelope; fusing the Mel-cepstrum, the linear prediction residual error, the harmonic energy ratio and the transient zero-crossing rate to construct a pathological feature matrix; extracting local, medium-range and global time sequence features through a three-branch parallel convolutional network; inputting a disease specific classifier to discriminate asthma, pneumonia and laryngitis respectively, and applying a feature decoupling regular term to improve interpretability. The system correspondingly realizes the modularized processing flow. According to the method, the cough sound collection quality and the disease subtype recognition accuracy in a complex environment are improved, meanwhile, the thermodynamic diagram is output to assist clinical decision making, and the diagnosis credibility and practicability are enhanced.

Apparatus and methods for deactivating bronchial nerves and ablating smooth muscle extending along a bronchial branch of a mammalian subject to treat asthma and related conditions. An ultrasonic transducer (11) is inserted into the bronchus as, for example, by advancing the distal end of a catheter (10) bearing the transducer into the bronchial section to be treated. The ultrasonic transducer emits ultrasound so as to heat tissues throughout a relatively large impact volume (13) to a temperature sufficient to inactivate nerve conduction and ablate smooth muscle but insufficient to cause rapid ablation or necrosis of the surrounding tissues. The treatment can be performed without locating or focusing on individual bronchial nerves or smooth muscle.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for relieving cough and asthma, and a preparation method and application thereof. The traditional Chinese medicine composition comprises, in mass parts, perilla seed 5-15 parts, radish seed 5-15 parts, white mulberry bark 5-15 parts, orange red or processed orange red 5-15 parts, and cassia 5-15 parts. The traditional Chinese medicine composition has the effect of relieving cough and asthma, can effectively improve the clinical symptoms such as cough, expectoration and wheezing of patients with chronic obstructive pulmonary disease, promote lung rehabilitation, improve the dyspnea condition of the patients, and improve the life quality of the patients.

The invention provides a traditional Chinese medicine composition for relieving cough and asthma and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-15 parts of herba ardisiae japonicae, 5-15 parts of honey-fried folium eriobotryae, 1-3 parts of honey-fried herba ephedrae, 2-5 parts of semen armeniacae amarae, 1-5 parts of roselle, 2-6 parts of mint, 2-6 parts of pericarpium citri reticulatae, 2-6 parts of caulis bambusae in taeniam, 4-12 parts of herba houttuyniae and 1-3 parts of honey-fried licorice root. The herba ephedrae is changed into the honey herba ephedrae, and the roselle is added, so that the product is weakened in sweating effect and more prominent in lung moistening and cough relieving, and is more suitable for weak people to use, and the applicable crowd is widened; meanwhile, a hydrotropy technology is adopted in the production and use process, so that the solubility of traditional Chinese medicine components is improved; the traditional Chinese medicine composition is taken after being mixed with warm water, solves the problem of overhigh alcohol content in the original product, is convenient to carry and adjustable in administration dosage, and is convenient for children and patients to use.

The present invention provides a composition for use in the prevention and / or treatment of a viral infection in an individual wherein the composition comprises Bifidobacterium longum subsp. Infantis and a mixture of HMO consisting of 2 '-fucosyllactose (2FL), difucosyllactose (DFL), lactose-N-tetraose (LNT), 6'-sialyllactose (6SL), 3 '-sialyllactose (3SL), and 3-fucosyllactose (3FL). The present invention also provides compositions for use in preventing and / or reducing the risk of allergen sensitization, preventing and / or reducing the risk of developing respiratory disorders in an individual, and / or preventing and / or reducing the risk of developing asthma in an individual.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating gastroesophageal reflux cough and a preparation method thereof. The traditional Chinese medicine composition disclosed by the invention is constructed by carefully selecting a medicine formula under the guidance of a traditional Chinese medicine theory and clinical experience and through a compatibility theory of monarch, minister, assistant and guide of traditional Chinese medicines. In the traditional Chinese medicine composition, the inula flower has the effects of promoting blood circulation, removing stasis and turbidity, clearing the airway and removing phlegm and fluid retention, and the mangnolia officinalis has the effects of promoting qi circulation, removing food retention, calming adverse-rising energy and relieving asthma, and both serve as monarch drugs; the dried orange peel has the effects of regulating qi and removing stagnation, the poria cocos has the effects of tonifying spleen, eliminating dampness and phlegm and breaking up the source of phlegm, and the bulbus fritillariae cirrhosae has the effects of clearing heat and moistening lung and resolving phlegm and relieving asthma; the rhizoma atractylodis macrocephalae has the effects of invigorating the spleen, replenishing qi, eliminating dampness and inducing diuresis, and the endothelium corneum gigeriae galli has the effects of promoting digestion and invigorating the stomach and is an assistant and guide drug. The whole prescription is ordered in monarch and minister, focuses on pathogenesis, is rigorous in prescription, has the effects of relieving cough and asthma, clearing heat and moistening lung, and strengthening spleen and stomach, and treats both symptoms and root causes of cough.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The invention discloses a preparation method of cough and asthma relieving granules, and belongs to the field of traditional Chinese medicine preparation, and the preparation method comprises the following steps: S1, sealed extraction to obtain a mixed solution: performing pulse type ultrasonic treatment on folium rhododendri daurici in an ethanol water solution for 1-3 minutes, then extracting for 66-78 hours at the temperature of 30-40 DEG C, and intermittently stirring; s2, filtering and squeezing to obtain an extracting solution; s3, concentrating the extracting solution to obtain a clear paste with the relative density of 1.10-1.2 at the temperature of 70-80 DEG C; s4, adjusting the pH value to 3.5-5.5, and removing astringency; s5, filtering with an ultrafiltration membrane, concentrating to obtain clear paste with the relative density of 1.10-1.2 at 70-80 DEG C, and spray-drying the clear paste to obtain extract powder; and S6, adding auxiliary materials into the extract powder, mixing, adjusting, preparing granules, drying, finishing the granules, screening, totally mixing, and sub-packaging to obtain the cough and asthma relieving granules. The extraction time is shortened, and the product stability is improved.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

The invention discloses a traditional Chinese medicine composition for treating cough. The invention belongs to the field of traditional Chinese medicine for treating cough. The traditional Chinese medicine composition is prepared from 17 traditional Chinese medicines including thunberg fritillary bulb, semen lepidii, platycodon grandiflorum, perilla leaf, almond, polygala tenuifolia, schisandra chinensis and the like. The cough is not injured by lung and cough, not injured by spleen and not coughed for a long time, and not injured by kidney and not cough and asthma, and the cough is not cured for a long time and is mostly caused by lung yin deficiency and kidney deficiency. Years of research finds that the fundamental cause of cough is lung qi upflow and phlegm obstructing lung regardless of external infection, internal injury and deficiency and excess symptoms, and the basic thought of treatment is to reduce phlegm and expel fluid retention; the lung qi is reduced; and tonifying spleen and kidney. According to the theory, the traditional Chinese medicines are screened according to the principle of syndrome differentiation and treatment of traditional Chinese medicine, and the prescription is an empirical prescription which is continuously explored and gradually formed in the practice process. The traditional Chinese medicine composition has a treatment effect on cough.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, R1-R4, n and m have the meanings given in the specification. The compounds of formula I exhibit GPR183 antagonistic activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases to which GRP183 antagonists are applicable, such as chronic pain, such as osteoarthritis, chronic lumbago, neuropathic pain, and immune system diseases, such as inflammatory bowel diseases, such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, and the like. , such as asthma and psoriasis.

The invention discloses an application of isothunberine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating asthma diseases. It is found that in an OVA-induced mouse asthma model, the isothunberine significantly reduces airway resistance excited by acetylcholine, improves inflammatory cell infiltration and airway mucus high secretion of asthma model mouse lung tissue, reduces the levels of lgE and OVA-lgE in serum and related inflammatory factors in alveolar lavage fluid, and has the effect of preventing and treating asthma. Therefore, the effect of treating asthma is achieved. Therefore, the isothunberine has the potential of preventing or treating the asthma, provides a new treatment mode for the treatment of the asthma, and has a wide application prospect.

The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).

The present disclosure provides interactive education systems, apparatus, components, and methods for teaching patient care. In some instances, devices, systems, and associated methods include air trapping techniques for asthma simulation. In some aspects of the present disclosure, a system comprises: a patient simulator having a simulated body portion; and an asthma simulation module positioned within the simulated body portion, the asthma simulation module including: a first simulated lung; an adjustable valve along a first air path between a simulated trachea and the first simulated lung; and an air trapping module along a second air path between the simulated trachea and the first simulated lung.

The utility model discloses a portable traditional Chinese medicine olfactory diagnosis instrument, which comprises a sample collection device, a gas enrichment device, a mass spectrometer, a data processor and a display, the mass spectrometer is sequentially connected with the data processor and the display, the gas enrichment device is test paper with an enrichment reagent encapsulating nano-metal particles, the enrichment efficiency is effectively improved, and the detection accuracy is improved. Therefore, the detection sensitivity and accuracy of the mass spectrometer are improved; the device is provided with the ion trap mass spectrometer, has the characteristics of high detection speed, high resolution and high sensitivity, and has performance advantages in qualitative and trace analysis aspects; and due to small volume and strong portability, the device can be conveniently integrated into portable or field detection equipment, can be used for auxiliary diagnosis of heart failure and asthma, and also has great clinical application value in the aspects of disease evolution and disease prognosis evaluation.

The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as potent inhibitors of transforming growth factor-beta receptor I (also known as activin receptor-like kinase 5) (TGFβRI) / ALK5. Other objects of the present invention are to provide processes for preparing these compounds; pharmaceutical compositions comprising an effective amount of these compounds; the use of said compounds for the preparation of a medicament for the treatment of pathological conditions or diseases which can be ameliorated by the inhibition of transforming growth factor-beta receptor I (TGFβRI) / ALK5, such as respiratory diseases, including idiopathic pulmonary fibrosis, asthma, COPD and lung cancer and skin and ocular fibrotic disorders.

This invention discloses a traditional Chinese medicine paste for clearing the lungs, resolving phlegm, relieving cough and asthma, and its preparation method, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine paste of this invention is mainly prepared from the following raw materials in parts by weight: 5-15 parts mulberry bark, 3-10 parts mulberry leaves, 3-10 parts apricot kernels, 5-15 parts ophiopogon japonicus, 5-15 parts glehnia littoralis, 3-10 parts earthworm, 8-30 parts roasted black sesame seeds, 3-10 parts loquat leaves, 8-30 parts clam shells, 8-30 parts reed rhizome, 5-15 parts trichosanthes root, 5-15 parts isatis root, 11-40 parts dried tangerine peel, 5-15 parts atractylodes macrocephala, 1-6 parts gastrodia elata, 5-15 parts buckwheat, 9-25 parts licorice root, 100-200 parts jujube, and 5-15 parts venison powder. The herbal paste of this invention has the effects of clearing the lungs and resolving phlegm, relieving cough and asthma, and also nourishing yin and moistening dryness, strengthening the spleen and stomach. It is suitable for cough, expectoration, and asthma caused by lung heat and yin deficiency, and internal accumulation of phlegm and heat. Preliminary animal experiments have verified that the herbal paste of this invention can significantly prolong the latency period of cough and reduce the frequency of cough. The soaking and decompression concentration processes in the preparation are all carried out under strict conditions, which can reduce the loss of effective ingredients and ensure the stability of product efficacy.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

Provided is a method for treating a condition selected from the group consisting of pain, sleep disorder, cancer, Alzheimer's disease, neurodegenerative diseases, ulcer, hypertension, opioid- related adverse effects, inflammation, asthma, glaucoma, neurodevelopment diseases and combinations thereof in a subject in need thereof, the method comprising administering to the subject: a) a first active pharmaceutical ingredient (API) comprising at least one cannabinoid other than CBD and THC; and b) a second API, which is different from the first API.

The invention relates to an infant asthma three-branch classification auxiliary judgment method and a medium, and relates to the technical field of data processing. The method comprises the following steps: collecting and preprocessing tidal respiration data and demographic data of infants, and performing heterogeneous feature extraction and grouping log-likelihood ratio acquisition on the preprocessed tidal respiration data and demographic data to obtain a log-likelihood ratio corresponding to each group; and performing hierarchical Bayesian fusion on each log-likelihood ratio to obtain a fusion result, and performing asthma risk auxiliary judgment of three-branch classification based on the fusion result. Compared with the prior art, the method can assist in judging the infant asthma more objectively and accurately based on the tidal respiration data.

This invention relates to catheter and handle assemblies for tissue treatment. More specifically, the invention relates to a catheter assembly having an elongated shaft, an ablation component coupled to one end of the shaft, and a handle coupled to the other end of the shaft. The handle facilitates axial and circumferential positioning of the ablation component via the shaft in an airway, tubing, or blood vessel for tissue treatment. Embodiments include using the handle during treatment of lung diseases such as COPD and asthma to facilitate axial and circumferential positioning of the shaft and ablation component through and independently of the working channel of a bronchoscope.

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

1. The name of the design product: packaging box (acupoint sticking treatment patch-cough and asthma). 2. The use of the design product: the outer packaging box of the product. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective drawing.

The application discloses a traditional Chinese medicine composition for preventing and treating chicken Bordetella, a preparation method and application thereof. The traditional Chinese medicine composition for preventing and treating chicken Bordetella comprises the following raw medicinal materials in parts by weight: one red 15-20 parts, Tianwen grass 15-20 parts, goldenrod 10-15 parts, Jixiang grass 10-15 parts, white yam 5-12 parts, Buddha's hand 5-12 parts and platycodon 5-10 parts. The traditional Chinese medicine composition adopts one red, Tianwen grass, goldenrod, Jixiang grass, white yam, Buddha's hand and platycodon for reasonable compounding, has the effects of clearing heat and cooling blood, relieving cough and asthma, and can effectively treat chicken Bordetella disease. The seven kinds of medicines are mixed to prepare an oral liquid, the seven kinds of medicines have a synergistic effect in the preparation process, the effects of the medicines are effectively exerted, and the effects of clearing heat and detoxifying, clearing heat and cooling blood, relieving cough and asthma are further enhanced. The composition is scientifically matched, has no obvious toxic side reaction and drug tolerance, and can provide a train of thought for solving the problem of antibiotic resistance.

According to the clausena lansium vinegar and the preparation method thereof, polygonatum odoratum and hawthorn are added in the fermentation process, pericarpium citri reticulatae, folium mori and honey are added after fermentation is completed, and the prepared clausena lansium vinegar product can neutralize in-vivo free radicals, promote lipid decomposition, relieve vascular inflammation response, lower the blood fat and blood sugar level and inhibit liver from synthesizing cholesterol; the added pericarpium citri reticulatae, radix polygonati officinalis, hawthorn, folium mori and honey have the effects of clearing heat, reducing pathogenic fire, resolving phlegm, relieving asthma, eliminating indigestion, reducing nodules and the like, and the effect of the clausena lansium vinegar can be enhanced.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.